text,label,importance,correlations
"India's Haldia Petrochemicals trading arm plans to scale up in Asia, sources say. HPL Global, the Singapore unit of India's Haldia Petrochemicals, plans to boost its trade volume by 30% to up to 2 million metric tons and double the number of traders in 2026, two industry sources familiar with the matter said on Wednesday.",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
"BMW to start iX3 production at plant in Hungary's Debrecen from next month. German luxury carmaker BMW will start series production of its iX3 electric model at a new plant in Debrecen, Hungary from the end of next month, the company said in a statement on Wednesday.",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
AstraZeneca's asthma drug fails main goal of COPD study. AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).,negative,critique,CA:WHEAT;LU:FINANCIAL_SERVICES;AU:WHEAT
"PostNL unveils 2028 strategy with focus on AI, e-commerce growth. PostNL announced its new strategy on Wednesday at its Capital Markets Day, targeting a normalized EBIT of over 175 million euros ($208 million) by 2028, as part of its vision to drive sustainable growth and innovation.",positive,générale,US:PETROLEUM_CRUDE;HK:SILVER
"Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025. - Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (""Dermata"" or the ""Company""), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARI™ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 being held in Paris, France, from September 17-20th. Details of the abstract are as follows: Abstract Title: Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris - Results from the STAR-1 Phase 3 Study Abstract Number: P3243 The full abstract will be released on Tuesday, September 16, 2025, at 10:00pm (PST).",neutral,générale,FR:BEVERAGES;FR:ELECTRICITY
"Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study. EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16 Dual-target Nanobody® VHH inhibiting TNF and OX40L being explored across a range of immune-mediated diseases Reaffirms Sanofi's commitment to addressing underlying inflammation across complex, heterogeneous chronic skin diseases Paris, September 17, 2025. New data from the HS-OBTAIN phase 2a study (clinical study identifier: NCT05849922) show that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS).",positive,importante,FR:FINANCIAL_SERVICES
"Alset AI Announces Voluntary Shareholder Lock-Ups Reflecting Confidence in Company's Long-Term Vision. VANCOUVER, BC / ACCESS Newswire / September 17, 2025 / Alset AI Ventures Inc.(TSXV:GPUS)(OTC:GPUSF)(WKN: A40M0J | SYM: 1R6)(""Alset AI"" or the ""Company"") an artificial intelligence (""AI"") venture company advancing innovation through strategic investment and cloud computing solutions, is pleased to announce that certain shareholders (the ""Locked-Up Shareholders"")beneficially owning or controlling, directly or indirectly, an aggregate of 13,010,068 common shares in the capital of the Company (the ""Shares""), representing approximately 8.39% of the Company's issued and outstanding Shares, have voluntarily agreed to a four-month lock-up periodon the Shares (the ""Voluntary Lock-Up""). The Locked-Up Shareholders includes two insiders of the Company, who together hold 2,638,750 Shares, representing approximately 1.70% of the Company's issued and outstanding Shares.",neutral,générale,CA:WHEAT;LU:FINANCIAL_SERVICES
"IDEX BIOMETRICS ASA SECURES 45,000 SENSOR SYSTEM ORDER AS DIGAWARE ACCELERATES NATIONWIDE ROLLOUT. IDEX BIOMETRICS HAS LANDED AN ORDER OF 45,000 FROM DIGAWARE, THE INNOVATIVE PRODUCT DIVISION OF EMNOVATE, COMPLETING THE SENSOR DELIVERY PIPELINE ANNOUNCED JANUARY 8, 2025. THIS MILESTONE ORDER POSITIONS DIGAWARE TO RAPIDLY SCALE THEIR BREAKTHROUGH BIOMETRIC ACCESS SOLUTIONS ACROSS AMERICA BEFORE EXPANDING GLOBALLY.",positive,importante,
"Oruka Therapeutics Announces $180 Million Private Placement. MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthcare Fund, Blackstone Multi-Asset Investing, Commodore Capital, Cormorant Asset Management, Deep Track Capital, Fairmount, Great Point Partners, LLC, Palo Alto Investors, LP, Perceptive Advisors, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners, Woodline Partners LP and a leading life sciences investment firm, among others.",negative,générale,DE:AIRCRAFT;FR:BEVERAGES
"111, Inc. Announces Second Quarter 2025 Unaudited Financial Results. Maintained Quarterly Operational Profitability Operating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoY Maintained Positive Operating Cash Flow in the First Half of the Year SHANGHAI , Sept. 17, 2025 /PRNewswire/ -- 111, Inc. (""111"" or the ""Company"") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025.",negative,générale,CA:WHEAT;LU:FINANCIAL_SERVICES;FR:AIRCRAFT
"Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001. Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent with the IL-23p19 class EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced interim data from its Phase 1 trial of ORKA-001, the Company's long-acting IL-23p19 antibody, in a late-breaking abstract at the European Academy of Dermatology and Venerology (EADV) Congress in Paris, France.",positive,importante,FR:FINANCIAL_SERVICES
"ADTRAN Holdings, Inc. Prices Upsized $175.0 Million Convertible Senior Notes Offering. HUNTSVILLE, Ala.--(BUSINESS WIRE)--ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) (the “Company”) today announced the pricing of its offering of $175.0 million aggregate principal amount of 3.75% convertible senior notes due 2030 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of.",negative,générale,DE:AIRCRAFT;FR:ELECTRICITY
"Informatica Named One of America's Best Midsize Companies by TIME Magazine and Honored by The Financial Times as One of Europe's Top Employers. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Informatica, a leader in enterprise AI-powered cloud data management, is proud to announce its latest round of recognition. Honored as one of TIME's America's Best Mid-Size Companies 2025, Named among Europe's Best Employers for 2025 by the Financial Times. These prestigious honors—presented in partnership with Statista—are a testament to Informatica's sustained commitment to employee satisfaction, responsible growth and sustainable business practices, and.",positive,générale,
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit. British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.,positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES;AU:WHEAT
"Empire Metals Limited Announces Appointment of Marketing Manager. LONDON, UK / ACCESS Newswire / September 17, 2025 / Empire Metals Limited (LON:EEE), the AIM-quoted and OTCQX-traded resource exploration and development company, is pleased to announce the appointment of a Marketing Manager, a key role which, along with Empire's partnership with titanium marketing experts, TiPMC Consulting, strengthens the in-house marketing and product development team and supports the rapid advancement of the Pitfield Titanium Project (""Pitfield"" or the ""Project"") in Western Australia. Key Points Appointment of Marketing Manager, Michael Tamlin, to lead product strategy and end-user engagement.",positive,générale,CA:WHEAT;LU:FINANCIAL_SERVICES
"INCYTE ANNOUNCES NEW 24-WEEK PHASE 3 DATA FROM THE STOP-HS CLINICAL TRIAL PROGRAM OF POVORCITINIB IN HIDRADENITIS SUPPURATIVA AT EADV 2025. WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #EADV25--INCYTE ANNOUNCES NEW 24-WEEK PHASE 3 DATA FROM THE STOP-HS CLINICAL TRIAL PROGRAM OF POVORCITINIB IN HIDRADENITIS SUPPURATIVA AT EADV 2025.",positive,importante,IN:IT_SERVICES
"Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety. Third Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / September 17, 2025 / Hemogenyx Pharmaceuticals plc is pleased to announce that the third patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in adults. The treatment was well tolerated and met the trial's predefined initial safety criteria.",positive,importante,CA:WHEAT;LU:FINANCIAL_SERVICES
"Perceived Risk Vs. Real Risk: Why NewtekOne's 2029 Notes Deserve A Strong Buy. NewtekOne, Inc. 8.625% Senior Notes due 2029 offer an attractive yield, reflecting market skepticism rather than true credit risk. Despite a business transition to a bank holding company and improved financials, NEWT's notes trade at a high yield due to a lack of Big Three ratings. Egan-Jones upgraded NEWT's credit rating to A-, but the market demands a premium, viewing NEWTH as riskier than its peers.",neutral,générale,CA:WHEAT;LU:FINANCIAL_SERVICES
"Australian Dollar Outlook: AUD/USD caught between Fed vote and jobs print. First impression of the AUD/USD hourly chart is one of clean lines before what promises to be a complex 24 hours. Even though many of the levels will be cannon fodder for whatever the Fed meeting dishes up, it provides something akin to a blueprint for traders to assess potential setups before the release of Australia's August employment report, an event that has flown under the radar this week despite being a key data point that may determine whether the RBA cuts rates again.",neutral,générale,
"Q1 2025 Dividend Exchange Rate. Q1 2025 Dividend Exchange Rate   Diversified Energy Company PLC (LSE:DEC, NYSE:DEC) announced on May 12, 2025 a dividend in respect of the first quarter ended March 31, 2025 in the amount of 29 cents per share (the “Q1 2025 Dividend”.)  The Company will pay the Q1 2025 Dividend on September 30, 2025, to those shareholders on the register on August 29, 2025.",neutral,générale,CA:WHEAT;LU:FINANCIAL_SERVICES;FR:AIRCRAFT
"Gold Breaks Record High – All Eyes on Fed's Next Move. The 4-hour chart of XAU/USD indicates that the price settled above the $3,650 level, the 100 Simple Moving Average (red, 4 hours), and the 200 Simple Moving Average (green, 4 hours). The upward move was such that the price spiked to $3,700.",neutral,générale,
BW Energy announces changes to the Executive Management team. BW Energy announces changes to the Executive Management team BW Energy appoints Brice Morlot as Chief Operating Officer and Thomas Young as Chief Financial Officer. Mr. Morlot joined BW Energy in 2024 as the Company's CFO.,neutral,générale,US:PETROLEUM_CRUDE;HK:SILVER
"Ethereum treasury firm The Ether Machine files with SEC to go public via Dynamix merger. The Ether Machine recently revealed raising 150,000 ETH for its corporate treasury, bringing its total holdings to 495,362 ETH.",positive,importante,
"Innate Pharma Reports First Half 2025 Business Update and Financial Results. MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma Reports First Half 2025 Business Update And Financial Results.",neutral,générale,
"EURUSD Elliott Wave Outlook: Bullish Impulse Structure Signals Further Gains. The short-term Elliott Wave analysis for EURUSD indicates an ongoing impulsive cycle that began on August 27. From that low, the pair has been advancing in a nested impulse structure.",positive,générale,
"Bitcoin Trend Constructive As Long As This Metric Holds, Glassnode Says. On-chain analytics firm Glassnode has explained how the Bitcoin price trend remains constructive as long as the asset trades above the short-term holder cost basis. Bitcoin Is Still Maintaining Above Short-Term Holder Realized Price In a new post on X, Glassnode has discussed about the Realized Price of the Bitcoin short-term holders.",positive,générale,
"EUR/GBP Outlook: Euro Favoured as Dollar Declines, British Pound Lags. The euro outperformed on Tuesday following stronger-than-expected ZEW sentiment data for Germany and the broader eurozone. The release reduced expectations of further ECB easing after last week's meeting, where policymakers held rates steady and described risks as “balanced” with the outlook in “a good place.",neutral,générale,
"MOVE price nears breakout as Movement Labs confirms Layer 1 blockchain transition. MOVE token is consolidating near resistance as traders react to Movement Labs' plan to transition into a Layer 1 blockchain. At the time of writing, the token was trading at $0.127, up 3.2% over the previous day.",neutral,générale,
"Crypto Market Holds Steady as Bitcoin and MYX Finance Lead Gains. The global crypto market is showing resilience, with the total market cap standing at $3.99 trillion after a $38 billion rise in the past 24 hours. However, the key resistance remains at $4.01 trillion.",positive,importante,
"Dogecoin Price Dip Sparks Institutional Buying Ahead of ETF Launch. Dogecoin (DOGE), the largest meme cryptocurrency by market value, has slipped nearly 5% this week to around $0.26. Despite the downturn, bargain hunters and institutional investors are seizing the opportunity.",negative,critique,IN:IT_SERVICES
"PAN GLOBAL APPOINTS ROGER DAVEY TO BOARD OF DIRECTORS. TSXV: PGZ   |   OTCQB: PGZFF   |   FRA: 2EU Roger Davey served as Chairman, Atalaya Mining, for a decade supporting the refurbishment, commissioning, and re-start of mining operations at the Riotinto Mine in Spain VANCOUVER, BC , Sept. 17, 2025 /PRNewswire/ - Pan Global Resources Inc. (""Pan Global"" or the ""Company"") (TSXV: PGZ) (OTCQB: PGZFF) (FRA: 2EU) is pleased to announce the appointment of UK-based mining executive Roger Davey to the Company's Board of Directors (the ""Board"").",positive,générale,
"Fed ‘third mandate' may devalue dollar, drive Bitcoin higher. Donald Trump's latest Fed pick cited a “third mandate” for the bank to moderate long-term rates, potentially justifying yield curve control policies, which could boost Bitcoin.",negative,importante,
